Illumina, Inc. ILMN
270.00
(3.90)
(1.42%)
as of 25 Sep
- Market cap
- $41.3B
- P/E
- 50.4×
Follow ILMN
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
Illumina, Inc. (ILMN) Return on assets
Illumina, Inc.'s return on assets over the twelve months to 30 June 2026 was 13.0%, down 0.2 percentage points from fiscal 2025 (13.1%). Over the past ten years it has ranged from −32.1% (fiscal 2022) to 15.2% (fiscal 2017); the current reading is higher than 64% of that period. That is above the Diagnostics & Research industry median of −6.71% and above the Healthcare sector median of −30.9%.
Return on assets, annual
Annual
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 13.1% | 28.03 |
| FY2024 | −14.9% | (4.52) |
| FY2023 | −10.4% | 21.69 |
| FY2022 | −32.1% | (38.75) |
| FY2021 | 6.68% | (2.12) |
| FY2020 | 8.80% | (5.24) |
| FY2019 | 14.0% | 0.52 |
| FY2018 | 13.5% | (1.70) |
| FY2017 | 15.2% | 3.60 |
| FY2016 | 11.6% | (1.53) |
Against its own ten years
Low −32.1%
High 15.2%
Ten-year median
11.6%
Current reading's percentile
64
Return on assets against peers
| Company | Return on assets |
|---|---|
| IDXX IDEXX Laboratories, Inc. compare | 33.7% |
| MTD Mettler-Toledo International, Inc. compare | 25.6% |
| ILMN Illumina, Inc. | 13.0% |
| A Agilent Technologies, Inc. compare | 11.0% |
| DGX Quest Diagnostics Incorporated compare | 6.43% |
| IQV IQVIA Holdings Inc. compare | 4.70% |
| WAT Waters Corporation compare | 1.13% |
| NTRA Natera, Inc. compare | −8.71% |
| GH Guardant Health, Inc. compare | −28.0% |
| Diagnostics & Research industry median | −6.71% |
| Healthcare sector median | −30.9% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on ILMN
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement